Kiniksa Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 3, 2021
Rhea-AI Summary
Kiniksa Pharmaceuticals (KNSA) is set to hold a conference call on August 3, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent corporate activities. The event will be accessible via a live webcast on the company’s website, with a replay available for 14 days post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet needs, leveraging a diverse portfolio including ARCALYST®, mavrilimumab, vixarelimab, and KPL-404.
Positive
- Kiniksa's portfolio includes innovative therapies targeting significant unmet medical needs.
- The upcoming conference call may provide insights into the company's financial performance and strategic direction.
Negative
- None.
Insights
Analyzing...
HAMILTON, Bermuda, July 20, 2021 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, August 3, 2021 at 8:30 a.m. Eastern Time to report its second quarter 2021 financial results and recent corporate and portfolio activity.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will be available on Kiniksa’s website for 14 days following the conference. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1485623.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio of assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts!™ Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
When will Kiniksa Pharmaceuticals report its Q2 2021 financial results?
How can I access Kiniksa Pharmaceuticals' conference call?
Where can I find the webcast for Kiniksa Pharmaceuticals' financial results?
What is Kiniksa Pharmaceuticals' focus as a biopharmaceutical company?
